Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             265 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 7 Acquired thalassemia in myelodysplastic syndrome: rare curiosity, or revealing condition? Steensma, D.P.
 2007
 31 S1 p. S4-S5
2 p.
 artikel
2 15 Active treatment – improving outcomes in del 5q patients List, A.F.
 2007
 31 S1 p. S9-
1 p.
 artikel
3 20 Acute myeloid leukaemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML): molecular and clinico-pathological features Falini, B.
 2007
 31 S1 p. S11-S12
2 p.
 artikel
4 4 Animal models of myelodysplasia: BCL-2 and mutant NRAS-mediated disease progression Padua, R.A.
 2007
 31 S1 p. S3-
1 p.
 artikel
5 Author Index 2007
 31 S1 p. S147-S155
9 p.
 artikel
6 29bis Haematopoietic growth factors in the treatment of neutropenia and thrombocytopenia of myelodysplastic syndromes Bowen, D.T.
 2007
 31 S1 p. S17-S18
2 p.
 artikel
7 C031 Allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndromes 50 years or older. A retrospective survey from the European Group for Blood and MarrowTransplantation Lim, Z.Y.
 2007
 31 S1 p. S39-S40
2 p.
 artikel
8 C032 Allogeneic hemopoietic stem cell transplantation for patients with myelodysplastic syndrome: the effect of blast count and disease status at transplant Bacigalupo, A.
 2007
 31 S1 p. S40-
1 p.
 artikel
9 C003 A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups Gilkes, A.F.
 2007
 31 S1 p. S24-
1 p.
 artikel
10 C017 Animal model of mitochondrial dysfunction generating macrocytic anemia and myelodysplastic bone marrow failure Thompson, J.E.
 2007
 31 S1 p. S31-S32
2 p.
 artikel
11 C016 A previous diagnosis of myelodysplastic syndrome has no influence on the clinical outcome of elderly patients with acute myeloid leukaemia Ferrara, F.
 2007
 31 S1 p. S31-
1 p.
 artikel
12 C026 Childhood refractory cytopenia: clinical, hematological features and response to immunosuppression Kratz, C.P.
 2007
 31 S1 p. S37-
1 p.
 artikel
13 C007 Chronic myelomonocytic leukemia (CMML) and CD4+/CD56+ plasmacytoid leukemia are two different phenotypic entities Martel, C.
 2007
 31 S1 p. S26-S27
2 p.
 artikel
14 C008 Clinical and molecular features in patients with juvenile myelomonocytic leukemia-like myeloproliferative disease and Noonan syndrome Kratz, C.P.
 2007
 31 S1 p. S27-
1 p.
 artikel
15 C010 Commercially available Array-CGH BAC platforms: pitfalls in interpreting results Barba, G.
 2007
 31 S1 p. S28-
1 p.
 artikel
16 C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion List, A.F.
 2007
 31 S1 p. S38-
1 p.
 artikel
17 C027 Cytopenias correlate with response to lenalidomide in del 5q MDS patients Sekeres, M.A.
 2007
 31 S1 p. S37-S38
2 p.
 artikel
18 C018 Del (20q), a benign clonal abnormality, involves totipotent stem cells in Shwachman Diamond Syndrome Crescenzi, B.
 2007
 31 S1 p. S32-S33
2 p.
 artikel
19 C001 Estimating the prevalence and pre-test likelihood of myelodysplasia: a retrospective review of bone marrow histopathology in 322 cases of unexplained cytopenia (s) in a teaching hospital Buckstein, R.
 2007
 31 S1 p. S23-
1 p.
 artikel
20 C023 Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes Pellagatti, A.
 2007
 31 S1 p. S35-
1 p.
 artikel
21 C019 Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del (5q) using high-density SNP arrays Wang, L.
 2007
 31 S1 p. S33-
1 p.
 artikel
22 C030 Hematopoietic stem cell transplantation after a myeloablative conditioning regimen in children with refractory cytopenia: results of a retrospective analysis from the EWOG-MDS group Locatelli, F.
 2007
 31 S1 p. S39-
1 p.
 artikel
23 C029 Hematopoietic stem cell transplantation for advanced primary MDS in children: results of a retrospective analysis from the EWOG-MDS group Zecca, M.
 2007
 31 S1 p. S38-S39
2 p.
 artikel
24 C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics Kern, W.
 2007
 31 S1 p. S27-S28
2 p.
 artikel
25 C020 Identification of novel genetic lesions in MDS using high density SNP-arrays Langemeijer, S.
 2007
 31 S1 p. S33-S34
2 p.
 artikel
26 C024 Impaired mitochondrial gene expression in MDS patients Schildgen, V.
 2007
 31 S1 p. S35-S36
2 p.
 artikel
27 C006 Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification Tomonaga, M.
 2007
 31 S1 p. S26-
1 p.
 artikel
28 C015 Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS) Pelz, D.
 2007
 31 S1 p. S30-S31
2 p.
 artikel
29 C014 Influence of different treatment strategies on the prognosis of patients with myelodysplastic syndromes (MDS) Nachtkamp, K.
 2007
 31 S1 p. S30-
1 p.
 artikel
30 C025 Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin Lim, Z.Y.
 2007
 31 S1 p. S36-S37
2 p.
 artikel
31 C011 Marked telomere loss following autologous stem cell transplantation may be predictive for the onset of secondary myelodysplastic syndrome/acute leukemia Ricca, I.
 2007
 31 S1 p. S28-S29
2 p.
 artikel
32 C005 New definitions for blast cells in AML and MDS with validation by virtual microscopy Goasguen, J.E.
 2007
 31 S1 p. S25-
1 p.
 artikel
33 C022 NPM1 monoallelic deletion in a subgroup of MDS/AML with del (5q) or monosomy 5 and complex karyotype La Starza, R.
 2007
 31 S1 p. S34-S35
2 p.
 artikel
34 11 Combination epigenetic therapy Garcia-Manero, G.
 2007
 31 S1 p. S7-
1 p.
 artikel
35 Committees 2007
 31 S1 p. iv-
1 p.
 artikel
36 C002 Polymorphisms of DNA-repair and detoxification enzymes in myelodysplastic syndromes Voso, M.T.
 2007
 31 S1 p. S23-S24
2 p.
 artikel
37 C012 Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes Mohamedali, A.
 2007
 31 S1 p. S29-
1 p.
 artikel
38 C004 Proposals of division for diagnostic accuracy in myelodysplastic syndromes Matsuda, A.
 2007
 31 S1 p. S24-S25
2 p.
 artikel
39 C021 SNP-array karyotyping complements routine metaphase cytogenetics in the detection of chromosomal aberrations including uniparental disomy in MDS Tiu, R.V.
 2007
 31 S1 p. S34-
1 p.
 artikel
40 C013 The influence of therapeutic strategies on survival in distinct cytogenetic subgroups – A collaborative study based on 3860 patients with MDS Schanz, J.
 2007
 31 S1 p. S29-S30
2 p.
 artikel
41 14 Cytogenetics of myelodysplastic syndromes and detection of del 5q Mufti, G.
 2007
 31 S1 p. S8-S9
2 p.
 artikel
42 27 Deferasirox – the novel, once a day oral iron chelator Goldberg, S.L.
 2007
 31 S1 p. S16-
1 p.
 artikel
43 10 DNA methyltransferase inhibition in the therapy of myelodysplastic syndromes Santini, V.
 2007
 31 S1 p. S6-S7
2 p.
 artikel
44 35 Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes? Gore, S.D.
 2007
 31 S1 p. S21-
1 p.
 artikel
45 Editorial board 2007
 31 S1 p. i-
1 p.
 artikel
46 1 Epidemiologic features in myelodysplastic syndromes Germing, U.
 2007
 31 S1 p. S1-
1 p.
 artikel
47 19 Genetics of chronic myeloproliferative disorders Skoda, R.
 2007
 31 S1 p. S11-
1 p.
 artikel
48 26 Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload Gattermann, N.
 2007
 31 S1 p. S15-S16
2 p.
 artikel
49 21 Immunophenotypic analysis of myelodysplastic syndromes Della Porta, M.G.
 2007
 31 S1 p. S12-S13
2 p.
 artikel
50 24 Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndrome Malcovati, L.
 2007
 31 S1 p. S14-
1 p.
 artikel
51 25 Improved survival in myelodysplastic syndromes patients receiving iron chelation therapy Leitch, H.A.
 2007
 31 S1 p. S15-
1 p.
 artikel
52 28 Increased apoptosis as a mechanism of ineffective erythropoiesis in myelodysplastic syndromes Invernizzi, R.
 2007
 31 S1 p. S16-S17
2 p.
 artikel
53 5 Insights into the molecular pathogenesis of myelodysplastic syndromes Nimer, S.D.
 2007
 31 S1 p. S3-S4
2 p.
 artikel
54 32 Is traditional low dose chemotherapy (cytarabine/melphalan) still an option? Bowen, D.
 2007
 31 S1 p. S19-S20
2 p.
 artikel
55 8 Molecular analysis of the 5q-syndrome Boultwood, J.
 2007
 31 S1 p. S5-S6
2 p.
 artikel
56 22 Myelodysplastic syndromes: molecular markers Wainscoat, J.S.
 2007
 31 S1 p. S13-
1 p.
 artikel
57 P057 Abrogation of the DNA-damage response in AML versus MDS cell lines Boehrer, S.
 2007
 31 S1 p. S71-
1 p.
 artikel
58 P076 Acquisition of RAS and JAK2 mutations contributes to progression of CMML from the dysplastic to the proliferative variant Onida, F.
 2007
 31 S1 p. S81-S82
2 p.
 artikel
59 P043 Activated monocytes contribute to bone marrow failure in myelodysplastic syndromes Meers, S.
 2007
 31 S1 p. S64-
1 p.
 artikel
60 P156 Allogeneic stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia (sAML): results from a single centre experience Tassara, M.
 2007
 31 S1 p. S125-S126
2 p.
 artikel
61 P042 Alteration in immune-effector cells in bone marrow of myelodysplastic syndrome patients Alfinito, F.
 2007
 31 S1 p. S63-S64
2 p.
 artikel
62 P145 A meta-analysis of the published studies and the long-term results of a large personal experience form the basis for an appropriate use of thalidomide in myelodysplastic syndromes Musto, P.
 2007
 31 S1 p. S120-
1 p.
 artikel
63 P096 AML/MDS with chromosome 5 and 7 abnormalities Stamatoullas, A.
 2007
 31 S1 p. S91-S92
2 p.
 artikel
64 P008 AML1/RUNX1 point mutations are frequent in MDS/AML among the residents of Semipalatinsk near former USSR nuclear test site Kimura, A.
 2007
 31 S1 p. S44-
1 p.
 artikel
65 P027 Analysis of cell cycle regulatory genes expression in the bone marrow of adult de novo myelodysplastic syndromes (MDS) Economopoulou, C.
 2007
 31 S1 p. S55-S56
2 p.
 artikel
66 P111 Analysis of modified WHO classification-based prognostic scoring system (WPSS) for Japanese MDS patients Araseki, K.
 2007
 31 S1 p. S100-
1 p.
 artikel
67 P062 An increase in aberrant p15INK4b gene methylation in myelodysplastic syndromes correlates with the number of bone marrow blasts and with the progression of the disease Baresova, P.
 2007
 31 S1 p. S73-S74
2 p.
 artikel
68 P054 Anti-erythroblast autoimmunity in early MDS Zaninoni, A.
 2007
 31 S1 p. S69-S70
2 p.
 artikel
69 P159 A reduced-intensity conditioning regimen for children with refractory cytopenia transplanted from an unrelated donor Strahm, B.
 2007
 31 S1 p. S127-
1 p.
 artikel
70 P030 A role for the endoplasmic reticulum in the apoptosis of erythroid precursors in low risk myelodysplastic syndromes Gyan, E.
 2007
 31 S1 p. S57-
1 p.
 artikel
71 18 Paroxysmal nocturnal hemoglobinuria Luzzatto, L.
 2007
 31 S1 p. S10-S11
2 p.
 artikel
72 P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS Sekeres, M.A.
 2007
 31 S1 p. S125-
1 p.
 artikel
73 P081 Assessment of myelodysplasia in MDS and secondary leukemia. Application of a scoring table to the WHO classification Andrieu, V.
 2007
 31 S1 p. S84-
1 p.
 artikel
74 P151 Azacitidine in combination with EPO+G-CSF and valproic acid rapidly determines hematological improvement in pretreated non responsive IPSS INT-1 MDS patients Santini, V.
 2007
 31 S1 p. S123-
1 p.
 artikel
75 P090 B7.1 expression on blasts in myelodysplastic syndromes Tamura, H.
 2007
 31 S1 p. S88-S89
2 p.
 artikel
76 P091 B7-H1 molecules on blasts in myelodysplastic syndromes Kondo, A.
 2007
 31 S1 p. S89-
1 p.
 artikel
77 P023 Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukemias and myelodysplastic syndromes Invernizzi, R.
 2007
 31 S1 p. S53-
1 p.
 artikel
78 P089 Biological significance of CD7-positive blasts in myelodysplastic syndromes Sato, C.
 2007
 31 S1 p. S88-
1 p.
 artikel
79 P007 Both HLA DRB1*11 and DRB1*15 are observed more frequently among patients with myelodysplastic syndrome compared to healthy controls Bakanay, S.M.
 2007
 31 S1 p. S44-
1 p.
 artikel
80 P079 BRAF mutations in juvenile myelomonocytic leukemia de Vries, A.C.H.
 2007
 31 S1 p. S83-
1 p.
 artikel
81 P077 C-FMS mutational analysis in chronic myelomonocytic leukemia (CMML) Such, E.
 2007
 31 S1 p. S82-
1 p.
 artikel
82 P088 Challenging diagnosis of refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS): detection of myeloid dysplasia by flow cytometry (FC) Font, P.
 2007
 31 S1 p. S87-S88
2 p.
 artikel
83 P093 Changes in the flowcytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes Westers, T.M.
 2007
 31 S1 p. S90-
1 p.
 artikel
84 P046 Characterization of the T-cell receptor repertoire in patients with myelodysplastic syndromes Momot, T.
 2007
 31 S1 p. S65-
1 p.
 artikel
85 P014 Chromosomal pattern study in hypocellular primary myelodysplastic syndrome and its correlation with clinical and cellular aspects de Souza, D.C.
 2007
 31 S1 p. S48-
1 p.
 artikel
86 P095 Chromosome 5q deletion in myelodysplastic syndrome Dwilewicz-Trojaczek, J.
 2007
 31 S1 p. S91-
1 p.
 artikel
87 P013 Chronic myelomonocytic leukemia (CMML): one disease with two phases or two different diseases? Symeonidis, A.
 2007
 31 S1 p. S47-S48
2 p.
 artikel
88 P113 Chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia Jeddi, R.
 2007
 31 S1 p. S101-
1 p.
 artikel
89 P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register Gioia, D.
 2007
 31 S1 p. S41-S42
2 p.
 artikel
90 P015 Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorised as unclassified (MDS/MPD-U) by WHO classification Breccia, M.
 2007
 31 S1 p. S48-S49
2 p.
 artikel
91 P153 Clinical effects of 5-azacitidine five days/monthly schedule in three symptomatic low-risk (IPSS: 0-1) myelodysplastic patients Fili, C.
 2007
 31 S1 p. S124-
1 p.
 artikel
92 P011 Clinical features and prognosis of patients with refractory cytopenia with multilineage dysplasia: results of multi-center analysis in Korea Cheong, J.-W.
 2007
 31 S1 p. S46-
1 p.
 artikel
93 P012 Clinical features and prognosis of patient with chromosome 5 abnormalities: results of multi-center analysis in Korea Cheong, J.-W.
 2007
 31 S1 p. S47-
1 p.
 artikel
94 P083 Clinical, hematological, cytogenetic and immunophenotypic profile in myelodysplastic syndrome patients in Rio de Janeiro, Brazil Ornellas de Souza, M.H.
 2007
 31 S1 p. S85-
1 p.
 artikel
95 P004 Clinico-hematologic and prognostic features of myelodysplastic syndromes of children inBelarus Klimkovich, N.
 2007
 31 S1 p. S42-S43
2 p.
 artikel
96 P065 Coamplification at 8q24 and 11q23 in AML/MDS cell lines MacLeod, R.A.F.
 2007
 31 S1 p. S75-
1 p.
 artikel
97 P143 Combination of erythropoietin and low-dose thalidomide for the management of anemia of low-grade myelodysplasia Leb, L.
 2007
 31 S1 p. S118-S119
2 p.
 artikel
98 P154 Combination of fludarabine and cytarabine as induction treatment of poor prognosis myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia (sAML): a single centre experience Crotta, A.
 2007
 31 S1 p. S124-S125
2 p.
 artikel
99 P123 Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey Steensma, D.P.
 2007
 31 S1 p. S106-
1 p.
 artikel
100 P099 Comparison of IWG 2006 and IWG 2000 response criteria for anemia of MDS in 419 patients: the GFM experience Kelaidi, C.
 2007
 31 S1 p. S93-
1 p.
 artikel
101 P116 Comparison of MDS patients with long survival to short survival patients. Analysis of cases with discrepancy between low IPSS and survival Neuwirtova, R.
 2007
 31 S1 p. S102-S103
2 p.
 artikel
102 P121 Coping with myelodysplastic syndromes (MDS): lessons learned from those living with the disease Thomas, M.L.
 2007
 31 S1 p. S105-
1 p.
 artikel
103 P018 Correlation between microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in myelodysplatic syndromes (MDS) Fracchiolla, N.S.
 2007
 31 S1 p. S50-S51
2 p.
 artikel
104 P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes Frytak, J.R.
 2007
 31 S1 p. S111-S112
2 p.
 artikel
105 P131 Cost of transfusion-dependent myelodysplastic syndromes (MDS) in Germany Kühne, F.
 2007
 31 S1 p. S111-
1 p.
 artikel
106 P021 Cytogenetic characterization by array comparative genomic hybridization and fluorescence in situ hybridization of mesenchymal stem cells from patients with myelodysplastic syndromes Lopez Villar, O.
 2007
 31 S1 p. S52-
1 p.
 artikel
107 P025 Dap-kinase hypermethylation and apoptosis in myelodysplastic syndromes Voso, M.T.
 2007
 31 S1 p. S54-
1 p.
 artikel
108 P142 Darbepoetin for the treatment of anemia of myelodysplastic syndromes: efficacy and quality of life Oliva, E.N.
 2007
 31 S1 p. S117-S118
2 p.
 artikel
109 P003 Data from the registry of the patients with myelodysplastic syndrome from Clinic of Hematology, Fundeni Clinical Institute, Bucharest, Romania. I. Epidemiological general data Gologan, R.
 2007
 31 S1 p. S42-
1 p.
 artikel
110 P068 Deletion of the ETV6/TEL gene in association with disruption of the MLL gene in a case of therapy-related myelodysplastic syndrome Lazaridou, A.
 2007
 31 S1 p. S76-S77
2 p.
 artikel
111 P118 Detection of cardiac iron by T2* MRI in transfusion dependent patients with acquired anemias Deplano, S.
 2007
 31 S1 p. S103-S104
2 p.
 artikel
112 P097 Detection of complex chromosome abnormalities in patients with myelodysplastic syndrome – involvement of chromosome 5 Lazaridou, A.
 2007
 31 S1 p. S92-
1 p.
 artikel
113 P052 Detection of humoral immune responses against Wilms tumor gene (WT1) product in patients affected by myelodysplastic syndromes Cilloni, D.
 2007
 31 S1 p. S68-S69
2 p.
 artikel
114 P063 Detection of methylation status changes in refractory anemia with ringed sideroblasts (RARS) by MS-MLPA Valencia, A.
 2007
 31 S1 p. S74-
1 p.
 artikel
115 P098 Diagnostic and prognostic significance of tryptase in clinical hematology: evaluation of 1041 patients Sperr, W.R.
 2007
 31 S1 p. S92-S93
2 p.
 artikel
116 P031 Differentiation of early stage myelodysplasic syndrome-deriving erythroid precursors by ectopic expression of NACA Stuhl, L.
 2007
 31 S1 p. S57-S58
2 p.
 artikel
117 P026 Different pattern of JNK activity in MDS-related versus de novo AML: implications for apoptosis-resistance and treatment failure in MDS-related AML Lagadinou, E.D.
 2007
 31 S1 p. S54-S55
2 p.
 artikel
118 P146 Disease progression in del (5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients Giagounidis, A.A.N.
 2007
 31 S1 p. S120-S121
2 p.
 artikel
119 P059 DNA instability in low-risk myelodysplastic syndromes – refractory anemia with or without ring sideroblasts Novotna, B.
 2007
 31 S1 p. S72-
1 p.
 artikel
120 P126 Do elderly patient suffering from myelodysplastic syndromes (MDS) have access to investigational drugs? Study of a French cohort of 82 MDS in a population-based sample 80 years and older Chaury, M.-P.
 2007
 31 S1 p. S108-
1 p.
 artikel
121 P064 Downregulation of microsomal carnitine palmitoyltransferase (mCPT) in myelodysplastic syndromes (MDS) – induced by hypermethylation and/or reduced carnitine availability Pfeilstöcker, M.
 2007
 31 S1 p. S74-S75
2 p.
 artikel
122 P029 Early progenitor cells antigens and apoptosis in patients with secondary myelodysplasia exposed to ionizing radiation after Chernobyl accident Ilyenko, I.
 2007
 31 S1 p. S56-S57
2 p.
 artikel
123 P060 Effect of azacitidine on PI-PLC-beta1 expression and Akt activation in a patient affected by high-risk myelodysplastic syndrome (MDS) Finelli, C.
 2007
 31 S1 p. S72-S73
2 p.
 artikel
124 P071 Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes Gyan, E.
 2007
 31 S1 p. S78-S79
2 p.
 artikel
125 P094 Erythroleukemia might be a possible erythroblastic transformation from myelodysplastic syndrome: molecular cytogenetic study on the clonality of erythroid lineage by immunomagnetic bead and immunophenotyping Kim, M.Y.
 2007
 31 S1 p. S90-S91
2 p.
 artikel
126 P050 Evidence for a role of CD4+CD25high Foxp3+ regulatory T-cells in the pathogenesis of myelodysplastic syndromes (MDS) Kotsianidis, I.
 2007
 31 S1 p. S67-S68
2 p.
 artikel
127 P140 Factors predicting for a favorable response among patients with myelodysplastic syndromes treated with erythropoietin ± G-CSF Symeonidis, A.
 2007
 31 S1 p. S116-S117
2 p.
 artikel
128 P016 Features of secondary myelodysplastic syndrome in persons who suffered from Chornobyl accident Dyagil, I.
 2007
 31 S1 p. S49-
1 p.
 artikel
129 P157 FLAMSA-RIC allogeneic transplantation yields superior results in myelodysplastic syndromes and secondary acute myelogenous leukemia Dobbelstein, C.
 2007
 31 S1 p. S126-
1 p.
 artikel
130 P086 Flow cytometry in myelodysplastic syndromes: a new tool in the classification and prognostification of low/int-I risk MDS van de Loosdrecht, A.A.
 2007
 31 S1 p. S86-S87
2 p.
 artikel
131 P020 Functional characterization of adult mesenchymal stromal cells from patients with myelodysplastic syndrome Boxberger, S.
 2007
 31 S1 p. S51-S52
2 p.
 artikel
132 P152 G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine Falke, E.
 2007
 31 S1 p. S123-S124
2 p.
 artikel
133 P073 Gene expression profiling in the myelodysplastic syndrome: patients with intermediate 1 versus higher risk Kracmarova, A.
 2007
 31 S1 p. S79-S80
2 p.
 artikel
134 P009 Genetic polymorphisms of DNA-repair- and detoxification enzymes in therapy-related AML and MDS Fischer, S.
 2007
 31 S1 p. S45-
1 p.
 artikel
135 P069 Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations Nowak, D.
 2007
 31 S1 p. S77-
1 p.
 artikel
136 P072 Genomic profiling of CD34+ and CD61+ cells in 5q-syndrome Lea, N.C.
 2007
 31 S1 p. S79-
1 p.
 artikel
137 P092 Granulocyte subpopulations in phenotypic pattern of MDS Vikentiou, M.
 2007
 31 S1 p. S89-S90
2 p.
 artikel
138 P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database Park, S.
 2007
 31 S1 p. S113-
1 p.
 artikel
139 P160 Hematopoietic stem cell transplantation for childhood MDS/JMML with pretransplant-chemotherapy Chung, N.-G.
 2007
 31 S1 p. S128-
1 p.
 artikel
140 P053 High cytotoxic potential of CD8+/granzymeB+/perforin+ T cells prevents leukemic outgrow of dysplastic hematopoietic precursor cells in patients with low/int-I risk myelodysplastic syndrome Chamuleau, M.E.D.
 2007
 31 S1 p. S69-
1 p.
 artikel
141 P141 High dose darbepoetin Q3W, alone or in combination with peg-filgrastim, for myelodysplastic syndromes unresponsive to recombinant erythropoietin Musto, P.
 2007
 31 S1 p. S117-
1 p.
 artikel
142 P028 High levels of telomerase activity in myelodysplastic syndromes are associated with eroded telomeres and shorter survival Zizkova, H.
 2007
 31 S1 p. S56-
1 p.
 artikel
143 P040 Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells Khan, R.
 2007
 31 S1 p. S62-S63
2 p.
 artikel
144 P006 Idiopathic cytopenia of uncertain significance (ICUS) versus low risk MDS: the diagnostic interface Valent, P.
 2007
 31 S1 p. S43-S44
2 p.
 artikel
145 P022 Impaired clonogenic and proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes Stavroulaki, E.
 2007
 31 S1 p. S52-S53
2 p.
 artikel
146 P049 Impaired T cell function and reduced peripheral tolerance mechanisms in myelodysplastic syndrome (MDS) Epling, P.K.
 2007
 31 S1 p. S67-
1 p.
 artikel
147 P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients Zanni, M.
 2007
 31 S1 p. S45-S46
2 p.
 artikel
148 P001 Incidence of myelodysplastic syndromes in the United States medicare population Goldberg, S.L.
 2007
 31 S1 p. S41-
1 p.
 artikel
149 P048 Increased apoptosis of circulating T cells in myelodysplastic syndromes Satoh, C.
 2007
 31 S1 p. S66-
1 p.
 artikel
150 P044 Increased expression of Toll-like receptor 4 and 9 in the bone marrow of patients with myelodysplastic syndromes Velegraki, M.
 2007
 31 S1 p. S64-S65
2 p.
 artikel
151 P110 Individualized IPSS in MDS by considering age, gender and FAB – a multicenter analysis Nösslinger, T.
 2007
 31 S1 p. S99-
1 p.
 artikel
152 P038 Inhibition of poly ADP ribose polymerase (PARP) induces cell death in leukaemic cell lines alone or synergistically with histone deacetylase inhibitors: potential for anti-leukaemia therapy Gaymes, T.J.
 2007
 31 S1 p. S61-S62
2 p.
 artikel
153 P106 Is cytogenetic follow-up useful in patients with myelodysplastic syndrome? A study of 119 analyses in 79 patients Pelizzari, A.M.
 2007
 31 S1 p. S97-
1 p.
 artikel
154 P056 Is the increased apoptosis a cause of impaired CD34+ B-cell precursors production in myelodysplastic syndromes? Sandes, A.F.
 2007
 31 S1 p. S70-S71
2 p.
 artikel
155 P075 JAK2 and MPL515 mutation analysis in RARS with platelets ≥500.000/μl and in RARS-T according to WHO (platelets ≥600.000/μl) Zipperer, E.
 2007
 31 S1 p. S80-S81
2 p.
 artikel
156 P150 Karyotype does not predict response to azacitidine in patients with myelodysplastic syndrome Juvvadi, R.
 2007
 31 S1 p. S122-S123
2 p.
 artikel
157 P158 Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer Milani, R.
 2007
 31 S1 p. S126-S127
2 p.
 artikel
158 P147 Management of haematological adverse events in MDS patients treated with lenalidomide Giagounidis, A.
 2007
 31 S1 p. S121-
1 p.
 artikel
159 P148 Management of non-haematological adverse events in MDS patients treated with lenalidomide Giagounidis, A.
 2007
 31 S1 p. S121-S122
2 p.
 artikel
160 P005 MDS incidence and mortality in UK General Practice Research Database Fryzek, J.P.
 2007
 31 S1 p. S43-
1 p.
 artikel
161 P061 Methylation status of the p15INK4b and p16INK4a genes in pediatric primary myelodysplastic syndrome Rodrigues, E.F.
 2007
 31 S1 p. S73-
1 p.
 artikel
162 P074 Molecular cytogenetic delineation of del (4q) in myelodysplastic syndromes with peripheral blood monocytosis La Starza, R.
 2007
 31 S1 p. S80-
1 p.
 artikel
163 P041 Monocyte and dendritic cell abnormalities in bone marrow of patients with myelodysplastic syndromes Reis, S.C.
 2007
 31 S1 p. S63-
1 p.
 artikel
164 P084 Morphological diagnosis of low grade myelodysplastic syndrome in childhood Baumann, I.
 2007
 31 S1 p. S85-
1 p.
 artikel
165 P080 Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome Benatti, C.
 2007
 31 S1 p. S83-S84
2 p.
 artikel
166 P085 Morphologic differential diagnosis of juvenile myelomonocytic leukemia (JMML) Karow, A.
 2007
 31 S1 p. S86-
1 p.
 artikel
167 P138 Myelodysplastic syndromes patients treated with recombinant erythropoietin show improved immunological functions Prutchi-Sagiv, S.
 2007
 31 S1 p. S115-
1 p.
 artikel
168 P078 No evidence for mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia de Vries, A.C.H.
 2007
 31 S1 p. S82-S83
2 p.
 artikel
169 PO007 A case of CD4+CD56+ lineage negative leukemia (DC2 leukemia) developed from myelodysplastic syndrome with the 5q deletion Ishikawa, M.
 2007
 31 S1 p. S132-
1 p.
 artikel
170 PO019 Acute myelogenous leukemia (AML) type induction chemotherapy for the patients with myelodysplastic syndrome (MDS) Kim, D.Y.
 2007
 31 S1 p. S138-
1 p.
 artikel
171 PO005 AML-like therapy in myelodysplastic syndromes: is there still a role? Molteni, A.
 2007
 31 S1 p. S131-
1 p.
 artikel
172 PO027 A new registry of myelodysplastic syndromes diagnosed in the Department of Haematology at Lausanne, Switzerland Knipp, S.
 2007
 31 S1 p. S142-
1 p.
 artikel
173 PO026 A rare case of pure erythroid leukemia in childhood, with cytogenetic abnormalities including 7 monosomy and 47, XXY. Probably a evolution of MDS Souto, E.X.
 2007
 31 S1 p. S141-S142
2 p.
 artikel
174 PO030 A rare history of a patient with acute myeloid leukaemia transformed in myelodysplastic syndrome Mehes, L.
 2007
 31 S1 p. S143-S144
2 p.
 artikel
175 PO024 Association of V617F JAK2 mutation and myelodysplastic 5q-syndrome without anemia Espanel, C.
 2007
 31 S1 p. S140-S141
2 p.
 artikel
176 PO022 Autoimmune phenomena, myelodysplastic syndromes, cytogenetics: a case report Crescenzi, B.
 2007
 31 S1 p. S139-S140
2 p.
 artikel
177 PO021 Characteristics and survival of 115 Irish patients with myelodysplastic syndrome: pilot study for establishment of a national database Enright, H.
 2007
 31 S1 p. S139-
1 p.
 artikel
178 PO028 Clinical and cytogenetic features of the secondary leukemias, induced by preceding antitumor treatment Vygovska, J.
 2007
 31 S1 p. S142-S143
2 p.
 artikel
179 PO025 Comparison of CFU-GM in patients with chronic myelomonocytic leukemia 1 and 2 (according to WHO classification), with typical myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD) Wiater, E.
 2007
 31 S1 p. S141-
1 p.
 artikel
180 PO004 Cytogenetic and clinical features of secondary myelodysplastic syndrome/acute myeloid leukemia: a single institutional study in Japan Ohyashiki, K.
 2007
 31 S1 p. S130-
1 p.
 artikel
181 PO009 Data from the registry of the patients with myelodysplastic syndrome from Clinic of Hematology, Fundeni Clinical Institute, Bucharest. II. Epidemiological demo-geographical data Gologan, R.
 2007
 31 S1 p. S133-
1 p.
 artikel
182 PO017 Deferiprone is useful in blood Russolillo, S.
 2007
 31 S1 p. S137-
1 p.
 artikel
183 PO032 Epidemiology and classification of MDS: 74 cases Bedoui, M.
 2007
 31 S1 p. S144-
1 p.
 artikel
184 PO023 High dose of r-EPO (40,000 IU) once a week is highly effective in a selected cohort of MDS patients with basal EPO level <250mu/ml, IPSS score ≤1.5 and low transfusional need Pierri, I.
 2007
 31 S1 p. S140-
1 p.
 artikel
185 PO014 In vitro growth modulation by L-ascorbic acid (L-AA) of colony forming cells from bone marrow of patients with refractory anemia (RA) Vlachaki, E.
 2007
 31 S1 p. S135-S136
2 p.
 artikel
186 PO008 Lactate dehydrogenase in patients with myelodysplastic syndromes Girtovitis, F.
 2007
 31 S1 p. S132-
1 p.
 artikel
187 PO013 Measurement of plasma and intracellular ascorbic acid (AA) levels in patients with myelodysplastic syndrome (MDS) by reverse phase high performance liquid chromatography (HPLC) Bekiari, E.
 2007
 31 S1 p. S135-
1 p.
 artikel
188 PO018 Measuring health-related quality of life impact of thrombocytopenia in MDS patients: results from a literature search Mathias, S.D.
 2007
 31 S1 p. S137-S138
2 p.
 artikel
189 PO011 Modelling the cost-effectiveness of Deferasirox (Exjade) in the treatment of iron overloaded myelodysplastic syndrome patients Karnon, J.
 2007
 31 S1 p. S134-
1 p.
 artikel
190 PO010 Myelodysplastic syndrome associated Gologan, R.
 2007
 31 S1 p. S133-S134
2 p.
 artikel
191 PO020 Primary MDS: analysis of survival and risk of leukemia transformation according to FAB, WHO, IPSS and WPSS classifications Velloso, E.R.P.
 2007
 31 S1 p. S138-S139
2 p.
 artikel
192 PO029 7q-MDS mimicking 5q-syndrome Braester, A.
 2007
 31 S1 p. S143-
1 p.
 artikel
193 PO033 Results of the treatment with erythropoietin in myelodysplastic syndrome in 25 patients from a single Romanian center Tatic, A.
 2007
 31 S1 p. S144-S145
2 p.
 artikel
194 PO016 Secondary leukemia in a patient with multiple myeloma treated by a standard protocol of chemotherapy and autologous bone marrow transplantation Lorand-Metze, I.
 2007
 31 S1 p. S136-S137
2 p.
 artikel
195 PO012 Should “not causally disease related” factors be included in prognostic scores? – Some remarks Tüchler, H.
 2007
 31 S1 p. S134-S135
2 p.
 artikel
196 PO001 Smoking is not a risk factor for fungal pneumonia in MDS and AML patients undergoing chemotherapy Knipp, S.
 2007
 31 S1 p. S129-
1 p.
 artikel
197 PO002 The clinical, hematological and morphological profile of patients with myelodysplastic syndromes: a single institution experienc Demirkan, F.
 2007
 31 S1 p. S129-
1 p.
 artikel
198 PO006 The impact of phenotypic abnormalities on survival of myelodysplastic syndromes Lorand-Metze, I.
 2007
 31 S1 p. S131-
1 p.
 artikel
199 PO015 Therapy-related MDS/AML after Belohlavkova, P.
 2007
 31 S1 p. S136-
1 p.
 artikel
200 PO003 Unrecognised coexistent myelodysplasia as a cause of poor prognosis multiple myeloma Várkonyi, J.
 2007
 31 S1 p. S130-
1 p.
 artikel
201 PO031 Withdrawn 2007
 31 S1 p. S144-
1 p.
 artikel
202 P032 Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome Ghoti, H.
 2007
 31 S1 p. S58-
1 p.
 artikel
203 P133 Patients with myelodysplastic syndromes (MDS) challenge transfusion resources now and in the future Plesnila-Frank, C.
 2007
 31 S1 p. S112-
1 p.
 artikel
204 P024 PKCz involvement in the impaired SDF1a-mediated migration of marrow CD34+ cells from MDS patients Thanopoulou, E.
 2007
 31 S1 p. S53-S54
2 p.
 artikel
205 P051 Polyclonal CD4+CD25high Foxp3+ regulatory T-cells are significantly increased in high risk myelodysplastic syndromes (MDS) Kordasti, S.
 2007
 31 S1 p. S68-
1 p.
 artikel
206 P058 Polymorphisms of glutathione S-transferase T1 and M1 in Greek patients with myelodysplastic syndrome in relation to patient characteristics and cytogenetic subgroups Stavropoulou, C.
 2007
 31 S1 p. S71-S72
2 p.
 artikel
207 P125 Pregnancy in patients with myelodysplastic syndromes (MDS) Volpicelli, P.
 2007
 31 S1 p. S107-
1 p.
 artikel
208 P117 Prevalence of cardiac disease among a US medicare population with myelodysplastic syndromes Goldberg, S.L.
 2007
 31 S1 p. S103-
1 p.
 artikel
209 P082 Primary myelodysplastic syndromes (MDS) with less than 5% of blasts in bone marrow: study of 147 patients from two centers in São Paulo, Brazil Velloso, E.R.P.
 2007
 31 S1 p. S84-S85
2 p.
 artikel
210 P067 Prion-like Doppel gene (PRND) aberrant expression in acute myeloid leukemias and myelodysplastic syndromes Invernizzi, R.
 2007
 31 S1 p. S76-
1 p.
 artikel
211 P114 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 37 patients Demirkan, F.
 2007
 31 S1 p. S101-S102
2 p.
 artikel
212 P115 Prognostic factors in chronic myelomonocytic leukaemia: a retrospective analysis of 113 patients Stamatoullas, A.
 2007
 31 S1 p. S102-
1 p.
 artikel
213 P112 Prognostic impact of bone marrow fibrosis in myelodysplastic syndromes (MDS) Baghikar, S.
 2007
 31 S1 p. S100-
1 p.
 artikel
214 P104 Prognostic role of transfusion requirement in myelodysplastic syndromes Salvi, F.
 2007
 31 S1 p. S96-
1 p.
 artikel
215 P103 Prognostic significance of LDH as a dynamic variable in myelodysplastic syndromes Sperr, W.R.
 2007
 31 S1 p. S95-
1 p.
 artikel
216 P127 Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the USA Sekeres, M.
 2007
 31 S1 p. S108-S109
2 p.
 artikel
217 P124 Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums Heptinstall, K.
 2007
 31 S1 p. S107-
1 p.
 artikel
218 17 Practical management of lenalidomide Giagounidis, A.
 2007
 31 S1 p. S10-
1 p.
 artikel
219 P134 Recombinant erythropoietin for transfusion-dependent myelodysplastic syndromes: long-term follow-up shows no modification of the natural history of treated patients and suggests a possible better prognosis for responders Musto, P.
 2007
 31 S1 p. S112-S113
2 p.
 artikel
220 P137 Response to erythropoietin (EPO) with or without differentiating treatment with 13-cis-retinoic-acid and dihydroxylated vitamin D3 in myelodysplastic syndromes (MDS) Ferrero, D.
 2007
 31 S1 p. S114-S115
2 p.
 artikel
221 P128 Retrospective survey highlights the iron burden in Japanese transfusion-dependent patients with MDS Takatoku, M.
 2007
 31 S1 p. S109-
1 p.
 artikel
222 P100 Retrospective WHO re-classification of 650 MDS patients diagnosed by FAB criteria: prognostic relevance Breccia, M.
 2007
 31 S1 p. S94-
1 p.
 artikel
223 P109 Revised IPSS cytogenetic categories and WHO classification allow a better prognostic definition of patients with de novo myelodysplastic syndromes (MDS) Bernasconi, P.
 2007
 31 S1 p. S98-S99
2 p.
 artikel
224 P107 Sequential molecular cytogenetic analysis of circulating CD34+ cells in MDS, a suitable method to monitor and predict response to 5-azacytidine Braulke, F.
 2007
 31 S1 p. S97-S98
2 p.
 artikel
225 P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670) Gattermann, N.
 2007
 31 S1 p. S109-S110
2 p.
 artikel
226 P035 Significance of bone marrow storage iron in patients with myelodysplastic syndromes Wong, L.
 2007
 31 S1 p. S60-
1 p.
 artikel
227 P045 T-cell receptor repertoire in patients with myelodysplastic syndromes (MDS) receiving lenalidomide treatment Momot, T.
 2007
 31 S1 p. S65-
1 p.
 artikel
228 P047 T-cell receptor (TCR) Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) van den Heuvel-Eibrink, M.M.
 2007
 31 S1 p. S66-
1 p.
 artikel
229 P144 Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS) Candoni, A.
 2007
 31 S1 p. S119-
1 p.
 artikel
230 P033 The Akt/mTOR signal transduction pathway is activated in high risk myelodysplastic syndromes and influences cell survival and proliferation Follo, M.Y.
 2007
 31 S1 p. S58-S59
2 p.
 artikel
231 P055 The decrease of B lymphocytes in MDS – what is the significance of it? Neuwirtova, R.
 2007
 31 S1 p. S70-
1 p.
 artikel
232 P120 The development of a frailty index for elderly patients with MDS Deschler, B.
 2007
 31 S1 p. S104-S105
2 p.
 artikel
233 P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML Boehrer, S.
 2007
 31 S1 p. S62-
1 p.
 artikel
234 P130 The importance of iron stores in the chelation treatment of patients with myelodysplastic syndromes Nielsen, P.
 2007
 31 S1 p. S110-S111
2 p.
 artikel
235 P119 The integration of comorbidity in decision making in myelodysplastic syndromes Stauder, R.
 2007
 31 S1 p. S104-
1 p.
 artikel
236 P108 The joint impact of cytogenetics, together with age, gender and classification on survival in MDS Makrai, A.
 2007
 31 S1 p. S98-
1 p.
 artikel
237 P105 The number of red blood cell transfusions is a significant but not an independent factor affecting survival in early MDS patients Cermak, J.
 2007
 31 S1 p. S96-S97
2 p.
 artikel
238 P036 The oral iron chelator ICL670 is a potent inhibitor of NF-kB and this activity is independent from iron overload in MDS cells Cilloni, D.
 2007
 31 S1 p. S60-S61
2 p.
 artikel
239 P102 Thrombocytopenia at diagnosis as an important independent negative prognostic marker for low risk MDS patients Jonasova, A.T.
 2007
 31 S1 p. S95-
1 p.
 artikel
240 P101 Thrombocytopenia in MDS: incidence and impact Kantarjian, H.
 2007
 31 S1 p. S94-S95
2 p.
 artikel
241 P019 TNF-alpha and VEGF serum levels in patients with different subtypes of MDS Serafyn, N.
 2007
 31 S1 p. S51-
1 p.
 artikel
242 P017 Transient leukemia in Down syndrome newborns Vallero, S.
 2007
 31 S1 p. S49-S50
2 p.
 artikel
243 P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program Fabre, C.
 2007
 31 S1 p. S122-
1 p.
 artikel
244 P037 Treatment with Epo/G-CSF of patients with low/int-I risk myelodysplastic syndrome diminishes relative CLIP (class II-associated invariant chain peptide) amount on hematopoietic precursor cells Chamuleau, M.E.D.
 2007
 31 S1 p. S61-
1 p.
 artikel
245 P136 Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need Jädersten, M.
 2007
 31 S1 p. S113-S114
2 p.
 artikel
246 P034 Urinary hepcidin excretion in patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF) Winder, A.
 2007
 31 S1 p. S59-S60
2 p.
 artikel
247 P087 Use of multiparametric flow cytometry analysis (six-color) for the detection of leukemia associated immunophenotypes (LAIP) in myelodysplastic syndromes (MDS) Campos, L.
 2007
 31 S1 p. S87-
1 p.
 artikel
248 P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients Goss, T.F.
 2007
 31 S1 p. S105-S106
2 p.
 artikel
249 P070 Whole genome association study in leukemia: frequent loss of heterozygosity in acute myeloid leukemia with a normal karyotype Cha, Y.
 2007
 31 S1 p. S78-
1 p.
 artikel
250 P066 WT1 expression in patients with myelodysplastic syndromes Polistina, M.T.
 2007
 31 S1 p. S75-S76
2 p.
 artikel
251 P139 WT1 gene expression decreases during erythropoietic growth factor treatment in MDS patients Oliva, E.N.
 2007
 31 S1 p. S116-
1 p.
 artikel
252 9 Refractory anemia with ringed sideroblasts Cazzola, M.
 2007
 31 S1 p. S6-
1 p.
 artikel
253 6 The immune pathophysiology of bone marrow failure and the emergence of clonal hematologic diseases Young, N.S.
 2007
 31 S1 p. S4-
1 p.
 artikel
254 3 Therapy-related myelodysplasia Pedersen-Bjergaard, J.
 2007
 31 S1 p. S1-S3
3 p.
 artikel
255 16 Treating non-del 5q patients with lenalidomide Schiffer, C.A.
 2007
 31 S1 p. S9-S10
2 p.
 artikel
256 13 Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO) Nand, S.
 2007
 31 S1 p. S8-
1 p.
 artikel
257 12 Treatment of myelodysplastic syndromes with azacitidine and thalidomide Kenealy, M.K.
 2007
 31 S1 p. S7-S8
2 p.
 artikel
258 29 Treatment of myelodysplastic syndromes with erythropoietin and G-CSF Hellstrom-Lindberg, E.
 2007
 31 S1 p. S17-
1 p.
 artikel
259 2 What is WHO in myelodysplastic syndromes? Bennett, J.M.
 2007
 31 S1 p. S1-
1 p.
 artikel
260 31 Which myelodysplastic syndromes patients are candidates for agressive chemotherapy? Sanz, G.F.
 2007
 31 S1 p. S19-
1 p.
 artikel
261 36 Which myelodysplastic syndromes patients are candidates for transplantation? de Witte, T.
 2007
 31 S1 p. S21-S22
2 p.
 artikel
262 33 Which myelodysplastic syndromes patients are candidates for treatment with azacitidine? Silverman, L.R.
 2007
 31 S1 p. S20-
1 p.
 artikel
263 34 Which myelodysplastic syndromes patients are candidates for treatment with decitabine? Lubbert, M.
 2007
 31 S1 p. S20-
1 p.
 artikel
264 30 Which myelodysplastic syndromes patients are candidates for treatment with hematopoietic growth factors? Fenaux, P.
 2007
 31 S1 p. S18-S19
2 p.
 artikel
265 23 WPSS, a dynamic prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes Malcovati, L.
 2007
 31 S1 p. S13-S14
2 p.
 artikel
                             265 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland